依托病毒特异性T细胞库满足即用型细胞治疗的需求
本文综述了病毒特异性T细胞(VST)在造血干细胞移植(HSCT)受者中治疗病毒相关疾病和恶性肿瘤的安全性与疗效,及其在HSCT外自体应用的前景。文章总结了迄今用于治疗病毒感染和恶性肿瘤的库藏VST(B-VST)临床试验的临床结局,并讨论了其作为靶向非病毒肿瘤的嵌合抗原受体平台的潜力,以及成为主流疗法前需克服的挑战。
要点
- 库藏VST(B-VST)可解决患者特异性VST制造耗时、费用高及供者/患者来源失败的问题。
- B-VST的主要挑战源于HLA不匹配导致的产品快速排斥和移植物抗宿主病。
- B-VST需与受者部分HLA匹配,其作为即用型疗法的临床结局和挑战是本文重点。
核心结论
- 高度表征的库藏VST(B-VST)可用于多个无关受者,具有吸引力,但需克服HLA不匹配相关的排斥和GVHD等挑战才能成为主流。
研究设计与样本
- 综述,总结迄今B-VST治疗病毒感染和恶性肿瘤的临床试验临床结局及其作为CAR平台潜力。
主要发现
- 过继转移VST在HSCT受者中治疗病毒相关疾病和恶性肿瘤显示显著安全性和疗效。
- 自体VST在HSCT外治疗病毒驱动恶性肿瘤也显示前景。
- 患者特异性VST制造时间阻碍急性病患者使用,且费用高、病毒未暴露供者和免疫抑制肿瘤致无反应患者常失败。
- B-VST主要挑战源于HLA多态性和免疫原性不匹配,需部分HLA匹配,否则导致快速排斥和GVHD。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adoptively transferred virus-specific T cells (VSTs) have shown remarkable safety and efficacy for the treatment of virus-associated diseases and malignancies in hematopoietic stem cell transplant (HSCT) recipients, for whom VSTs are derived from the HSCT donor. Autologous VSTs have also shown promise for the treatment of virus-driven malignancies outside the HSCT setting. In both cases, VSTs are manufactured as patient-specific products, and the time required for procurement, manufacture, and release testing precludes their use in acutely ill patients. Further, Good Manufacturing Practices-compliant products are expensive, and failures are common in virus-naive HSCT donors and patient-derived VSTs that are rendered anergic by immunosuppressive tumors. Hence, highly characterized, banked VSTs (B-VSTs) that can be used for multiple unrelated recipients are highly desirable. The major challenges facing B-VSTs result from the inevitable mismatches in the highly polymorphic and immunogenic human leukocyte antigens (HLA) that present internally processed antigens to the T-cell receptor, leading to the requirement for partial HLA matching between the B-VST and recipient. HLA mismatches lead to rapid rejection of allogeneic T-cell products and graft-versus-host disease induced by alloreactive T cells in the infusion product. Here, we summarize the clinical outcomes to date of trials of B-VSTs used for the treatment of viral infections and malignancies and their potential as a platform for chimeric antigen receptors targeting nonviral tumors. We will highlight the properties of VSTs that make them attractive off-the-shelf cell therapies, as well as the challenges that must be overcome before they can become mainstream.
引用
- Quach DH, Lulla P, Rooney CM, et al. Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies. Blood. 2023. PMID: 36574622. doi:10.1182/blood.2022016202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。